Agile Therapeutics, Inc. (AGRX)

NASDAQ: AGRX · IEX Real-Time Price · USD
1.39
0.04 (2.96%)
May 26, 2022 3:31 PM EDT - Market open

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year2021202020192018201720162015201420132012
Revenue
4.10.7500000000
Revenue Growth (YoY)
447.53%---------
Cost of Revenue
10.720.2800000000
Gross Profit
-6.620.4700000000
Selling, General & Admin
58.1436.0298.7412.388.797.475.153.575.93
Research & Development
6.2513.59.869.7814.4320.9325.6213.379.1517.39
Other Operating Expenses
0001.02000000
Operating Expenses
64.3949.5218.8619.5426.8129.7233.0918.5212.7323.32
Operating Income
-71.01-49.05-18.86-19.54-26.81-29.72-33.09-18.52-12.73-23.32
Interest Expense / Income
3.913.1101.121.922.452.081.571.510.14
Other Expense / Income
-0.03-0.31-0.25-0.4-0.43-0.351.14-0.350.08-0.2
Pretax Income
-74.89-51.85-18.61-20.26-28.3-31.82-36.31-19.73-14.32-23.26
Income Tax
000-0.480-3.08-5.97-3.6500
Net Income
-74.89-51.85-18.61-19.78-28.3-28.74-30.34-16.08-14.32-23.26
Preferred Dividends
0000000000.6
Net Income Common
-74.89-51.85-18.61-19.78-28.3-28.74-30.34-16.08-14.32-23.86
Shares Outstanding (Basic)
2211111000
Shares Outstanding (Diluted)
2211111000
Shares Change
14.63%71.31%44.05%10.91%9.43%28.41%93.22%22929.43%25.20%-
EPS (Basic)
-30.80-24.40-15.20-23.20-36.40-40.80-55.20-56.40-11.00-24.00
EPS (Diluted)
-30.80-24.40-15.20-23.20-36.40-40.80-55.20-56.40-11.00-24.00
Free Cash Flow Per Share
-26.98-22.51-12.78-20.06-33.45-33.01-46.81-51.25-14.00-30.00
Gross Margin
-161.35%62.35%--------
Operating Margin
-1731.41%-6549.13%--------
Profit Margin
-1826.24%-6922.96%--------
Free Cash Flow Margin
-1596.46%-6363.68%--------
Effective Tax Rate
0.00%0.00%0.00%2.35%0.00%9.66%16.45%18.51%0.00%0.00%
EBITDA
-68.76-48.47-18.44-19.12-26.36-29.35-34.21-18.15-12.8-23.1
EBITDA Margin
-1676.59%-6471.03%--------
EBIT
-70.98-48.74-18.61-19.14-26.39-29.37-34.23-18.16-12.81-23.12
EBIT Margin
-1730.80%-6507.88%--------
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).